Navigation Links
BioMS Medical warrant extension
Date:3/2/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that effective on March 16, 2009 the exercise term of 11,500,000 share purchase warrants, each of which entitles the holder to purchase one Class A common share at a price of $5.00 per share, will be extended from March 23, 2009 to December 31, 2009.

On March 18, 2008, BioMS Medical's Board of Directors passed a resolution to extend 10,514,000 of the warrants, the portion held by warrant holders who are at arm's length to the Company. At the Company's annual general meeting held on May 9, 2008, the shareholders holding a majority of the Class A common shares, excluding the votes attached to Class A common shares held by insiders whose warrants were being amended, approved the extension for the remaining 986,000 warrants held by insiders.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Research and Markets  has announced the addition of ... Chromatograph Market by Type , Technology, Spectroscopy, Gas chromatography, ... to 2013 - 2020" report to their offering. ... analytical instrument that provides chemical composition data on process ... which companies carry out their production and improve the ...
(Date:9/29/2014)... ACEA Biosciences, Inc. (ACEA) has ... iCELLigence Research Grant for his proposal on cancer ... an impedance based real-time label-free cellular analysis instrument. ... Biomedical Engineering at Yale University currently holds a ... Professor Rong Fan's laboratory involve the ...
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - SQI ... company that develops and commercializes proprietary technologies and products ... appointment of Peter Winkley to Chairman of ... Ricks .  Mr. Ricks will continue to serve as ... provide leadership to the Company.  "We ...
(Date:9/29/2014)... 2014  The 12th Cold Chain GDP & ... September 29 at the John B. Hynes Convention Center. ... for a weeklong conference attracting industry executives ... is designed to cover the industry,s most pressing topics, ... all temperature range products, GDP compliance requirements and supply ...
Breaking Biology Technology:Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2SQI Diagnostics Announces New Chairman of Board of Directors 212th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2
... KYOTO, Japan and MARCY L,ETOILE, France , ... today that they have entered into a partnership to ... microbiology laboratories. bioMerieux will work with Shimadzu and their ... spectrometry technology for optimized integration into the microbiology laboratory ...
... , May 21 Micromet, Inc. (Nasdaq: MITI ... next-generation antibodies for the treatment of cancer, today announced that updates ... at two upcoming medical conferences. , ... Blinatumomab (MT103), the Company,s lead product candidate, will ...
... , BRISBANE, Calif. , May 21 InterMune, Inc. (Nasdaq: ... Medical Officer and Senior Vice President, Clinical Affairs of InterMune, will present at ... May 26 at 3 p.m. EDT . , ... To access a live audio webcast of the presentation, investors ...
Cached Biology Technology:Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 2Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 3Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 4Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences 2Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences 3InterMune to Present at 2010 Citi Health Care Conference 2
(Date:9/29/2014)... inhibitor dabrafenib has significant anti-tumour activity in patients ... cancer whose disease has progressed after chemotherapy, according ... 2014 Congress in Madrid, Spain. , "Reports ... generated considerable interest because these mutations may be ... agents," says lead author Dr David Planchard, pulmonary ...
(Date:9/29/2014)... in French . ... of days an expectant mother was deprived of electricity ... of her child, a new study finds., Scientists from ... have detected a distinctive ,signature, in the DNA of ... ice storm. Five months after the event, researchers recruited ...
(Date:9/29/2014)... a previously unknown mechanism by which estrogen prepares ... of estrogen-positive breast cancers, resist cancer drugs. The ... breast cancer therapy and will help doctors predict ... The University of Illinois team reports its findings ... pre-activates the unfolded-protein response (UPR), a pathway that ...
Breaking Biology News(10 mins):Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... world over, are hungry for more meat, milk and ... has prompted explosive growth in livestock production and massive ... new textbook, Animal Manure Recycling: Treatment and Management, draws ... to put environmental problems to work and ensure the ...
... Department of Energy is making good on the second phase of ... study led by Dr. Joshua Yuan, Texas A&M AgriLife Research plant ... Yuan, who was granted $1.8 million for Phase I ... potential fuel source., The scientist said his research is moving ahead ...
... a new model for a genetic eye disease, and shows ... monkeys can yield valuable information about the human brain. ... of the Society for Neuroscience and the world,s largest source ... models have long been central in how we understand the ...
Cached Biology News:New textbook tackles the sustainable recycling of manure 2Plant fuel project moves to second phase under US Energy Department grant 2Understanding ourselves by studying the animal kingdom 2
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Biology Products: